Updates are available Correction dated 2023-03-20
Click to view Correction: https://doi.org/10.1038/s41408-023-00814-w
-
Authors
Rögnvaldsson, Sæmundur http://orcid.org/0000-0003-2162-8414
Love, Thorvardur Jon
Thorsteinsdottir, Sigrun http://orcid.org/0000-0001-5017-3530
Reed, Elín Ruth
Óskarsson, Jón Þórir http://orcid.org/0000-0002-9201-1166
Pétursdóttir, Íris
Sigurðardóttir, Guðrún Ásta
Viðarsson, Brynjar
Önundarson, Páll Torfi
Agnarsson, Bjarni A.
Sigurðardóttir, Margrét
Þorsteinsdóttir, Ingunn
Ólafsson, Ísleifur
Þórðardóttir, Ásdís Rósa
Eyþórsson, Elías
Jónsson, Ásbjörn
Björnsson, Andri S.
Gunnarsson, Gunnar Þór
Pálsson, Runólfur
Indriðason, Ólafur Skúli
Gíslason, Gauti Kjartan http://orcid.org/0000-0003-4710-0781
Ólafsson, Andri
Hákonardóttir, Guðlaug Katrín
Brinkhuis, Manje http://orcid.org/0000-0001-6371-7218
Halldórsdóttir, Sara Lovísa
Ásgeirsdóttir, Tinna Laufey
Steingrímsdóttir, Hlíf
Danielsen, Ragnar
Dröfn Wessman, Inga
Kampanis, Petros
Hultcrantz, Malin
Durie, Brian G. M.
Harding, Stephen
Landgren, Ola http://orcid.org/0000-0001-6485-4839
Kristinsson, Sigurður Yngvi http://orcid.org/0000-0002-4964-7476
- License Information
-
More Information
Article History
Received: 9 December 2020
Revised: 31 March 2021
Accepted: 13 April 2021
First Online: 17 May 2021
Change Date: 20 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-023-00814-w
Conflict of interest
: P.K. is an employee of The Binding Site. BGMD has done consultancy for Amgen, Janssen, Celgene, Takeda. S.H. is the director of The Binding Site. O.L. has received research funding from: National Institutes of Health (NIH), National Cancer Institute (NCI), U.S. Food and Drug Administration (FDA), Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), Leukemia and Lymphoma Society (LLS), Perelman Family Foundation, Rising Tide Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; Honoraria/ad boards: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and serves on Independent Data Monitoring Committees (IDMCs) for clinical trials lead by Takeda, Merck, Janssen, Theradex. S.Y.K. has received research funding from International Myeloma Foundation, European Research Council, Icelandic Center for Research (Rannís), Amgen, Celgene. The remaining authors declare no competing interests.
